We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Diagnostic Products Detect Prostate Cancer

By LabMedica International staff writers
Posted on 19 Jun 2017
A novel sample collection device was designed to support a urine-based non-invasive "liquid biopsy" molecular diagnostic test that determines the risk for developing high-grade prostate cancer.

The biomedical company MDxHealth SA (Herstal, Belgium) has announced the European launch of its CE-marked UrNCollect device for use with the SelectMDx in vitro diagnostic (IVD) PCR test kit for prostate cancer.

UrNCollect is a user-friendly device that enables the hygienic and standardized collection of the first 16 milliliters of the urine stream and reduces laboratory errors by automating preservative mixing without additional handling or pipetting.

The SelectMDx PCR kit enables diagnostic laboratories with manual and automated RNA extraction and PCR platforms to perform the liquid biopsy test in their own facility. More...
Laboratories that are not equipped to use the IVD PCR kit can have samples processed at MDxHealth’s state-of-the-art ISO-certified diagnostic facilities in Nijmegen, the Netherlands or Irvine, California, USA.

“Many of our current customers are eager to start using the IVD PCR kit so they can run the SelectMDx for prostate cancer test in their own labs,” said Dr. Jan Groen, CEO of MDxHealth. “It is well-timed that our UrNCollect device is launching as a complement to the SelectMDx IVD PCR kit because pilot studies demonstrated that patients and physicians found the device easier to use than traditional urine collection tubes.”

A technical validation study that assessed and confirmed the robustness, reproducibility, and interlaboratory performance of SelectMDx was published in the May 11, 2017, issue of the journal Translational Medicine Communications.

Related Links:
MDxHealth


New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Portable Electronic Pipette
Mini 96
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The genomic test measures eight gene activities in a melanoma tumor and combines this data with patient factors like age and tumor thickness (Photo courtesy of 123RF)

Genomic Test Could Reduce Lymph Node Biopsy Surgery in Melanoma Patients

Accurately determining whether melanoma has spread to the lymph nodes is crucial for guiding treatment decisions, yet the standard procedure—sentinel lymph node biopsy—remains invasive, costly, and unnecessary... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.